AZIVOC 250 Tablets contain Azithromycin 250 mg, a broad-spectrum macrolide antibiotic indicated for the treatment of a wide range of bacterial infections. It is effective against susceptible organisms causing respiratory tract infections, ear, nose, and throat infections, skin and soft tissue infections, and certain sexually transmitted infections. With its excellent tissue penetration and prolonged half-life, AZIVOC 250 provides sustained antibacterial activity, allowing for convenient once-daily dosing and improved patient compliance.
Azithromycin works by inhibiting bacterial protein synthesis, preventing the growth and multiplication of susceptible bacteria. Its broad antimicrobial spectrum and favorable safety profile make it a trusted choice for healthcare professionals in both outpatient and hospital settings. AZIVOC 250 helps reduce infection-related symptoms, promotes faster recovery, and minimizes the risk of complications when used as prescribed.
Research & Clinical Data for AZIVOC 250
Indications Supported by Clinical Evidence
- Upper & Lower Respiratory Tract Infections: Effective in the treatment of bacterial pharyngitis, tonsillitis, sinusitis, bronchitis, and community-acquired pneumonia caused by susceptible organisms.
- Ear, Nose & Throat (ENT) Infections: Demonstrated efficacy in treating acute otitis media and bacterial sinus infections.
- Skin and Soft Tissue Infections: Effective against susceptible organisms causing cellulitis, impetigo, and other cutaneous infections.
- Other Susceptible Bacterial Infections: Used in the management of various bacterial infections based on culture and sensitivity results and clinical judgment.